Debiopharm Group and Ipsen complete European decentralised registration of Decapeptyl

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical Group, announced that the 6-month sustained-release formulation of Decapeptyl® (triptorelin embonate 22.5 mg) successfully completed its European decentralised registration procedure involving nine countries: Germany (reference member state), France, Austria, Finland, Norway, Belgium, Denmark, Spain and The Netherlands.

Triptorelin embonate 22.5 mg is Debiopharm’s new 6-month-formulation of a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer. Debiopharm has licensed the European marketing rights to Ipsen. The first European countries to launch the 6-month formulation should be Germany, The Netherlands and Spain.

“As expected, we are proud to offer patients suffering from prostate cancer a new 6-month formulation of Decapeptyl® with an improved convenience and a consistent and similar efficacy to the already established 1 and 3-month formulations,” said Jean-Luc Bélingard, Ipsen’s Chairman and Chief Executive Officer. “The completion of this procedure represents a major step forward in the development of our uro-oncology franchise.”

“It is great news that the completion of the European decentralised procedure for triptorelin embonate 6-month formulation was done in such a timely manner,” added Rolland-Yves Mauvernay, President and Founder of Debiopharm Group. “We view this achievement as further evidence of the efficacy and safety of this important product. LHRH-agonists will remain the mainstay of hormone-dependent prostate cancer in the years ahead, and patients can now look forward to receiving a more convenient treatment every six months instead of every three months.”


 Debiopharm Group


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Drug combination may reduce the risk of prostate cancer progression, death